For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

By Raechel Thankam Job July 9 (Reuters) - AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis, ...

Astrazeneca (NYSE:AZN) told investors and analysts that it is continuing to embed sustainability into its business strategy ...

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca.

Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...

AstraZeneca's stock tumbled after the pharmaceutical company said its Wainua drug failed to meet the primary target in a late-stage clinical trial for heart disease, denting investor hopes for ...

The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions ...

Texas Attorney General Ken Paxton announced Monday that his office has reached a settlement with AstraZeneca Pharmaceuticals ...

July 9 () - AstraZeneca ‌said on ‌Thursday that ​its drug Wainua, made ‌in ⁠partnership with Ionis, ⁠failed to ​meet ​the ...

Sino Biopharmaceutical inks a licensing deal with AstraZeneca for a respiratory drug, with milestones and royalties worth ...

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...